What are the stages and management strategies for a patient with heart failure, including optimization of medical therapy and addressing underlying comorbidities, such as hypertension and diabetes?

Heart Failure Stages and Classification

ACC/AHA Staging System

Heart failure is classified into four progressive stages (A through D), with Stage A representing patients at risk but without structural disease, and Stage D representing refractory heart failure requiring specialized interventions. 1

Stage A: At High Risk for Heart Failure

• Patients with hypertension, atherosclerotic disease, diabetes mellitus, obesity, metabolic syndrome, family history of cardiomyopathy, or exposure to cardiotoxins 1
• No structural heart disease or symptoms present 1
• Management focuses on aggressive risk factor modification and prevention 1

Stage B: Structural Heart Disease Without Symptoms

• Patients with left ventricular remodeling including LV hypertrophy, reduced ejection fraction, or asymptomatic valvular disease 1
• No current or prior symptoms of heart failure 1
• Treatment includes ACE inhibitors or ARBs and beta-blockers in appropriate patients to prevent progression 1

Stage C: Structural Heart Disease With Current or Prior Symptoms

• Patients with marked symptoms despite medical therapy, including shortness of breath and fatigue 1
• This stage requires comprehensive guideline-directed medical therapy (GDMT) 1

Stage D: Refractory Heart Failure

• Patients recurrently hospitalized or cannot be safely discharged without specialized interventions 1
• Requires consideration of mechanical circulatory support, transplantation, or palliative care 1

---

Management Strategy by Heart Failure Type

Heart Failure with Reduced Ejection Fraction (HFrEF, EF ≤40%)

Foundational Quadruple Therapy (Initiate Simultaneously)

All patients with symptomatic HFrEF (NYHA Class II-IV) should immediately start four medication classes simultaneously: an SGLT2 inhibitor, a mineralocorticoid receptor antagonist (MRA), a beta-blocker, and an ARNI (or ACE inhibitor/ARB if ARNI not tolerated), which provides approximately 73% mortality reduction and 5.3 additional life-years compared to no treatment. 2

1. SGLT2 Inhibitors (Start First)

• Dapagliflozin 10 mg once daily or Empagliflozin 10 mg once daily 2
• Reduces cardiovascular death and HF hospitalization regardless of diabetes status 2
• Minimal blood pressure effect (only -1.50 mmHg in patients with baseline SBP 95-110 mmHg) 2
• No dose titration required; maximal benefit at starting dose 2
• Can be used if eGFR ≥20 mL/min/1.73 m² (dapagliflozin) or ≥30 mL/min/1.73 m² (empagliflozin) 2

2. Mineralocorticoid Receptor Antagonists (Start First)

• Spironolactone 12.5-25 mg once daily or Eplerenone 25 mg once daily 2
• Provides at least 20% mortality reduction and reduces sudden cardiac death 2
• Minimal blood pressure effect, allowing early initiation 2
• Can be used if eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L 1, 2
• Target dose: Spironolactone 25-50 mg daily or Eplerenone 50 mg daily 2

3. Beta-Blockers (Evidence-Based Only)

• Carvedilol, metoprolol succinate, or bisoprolol ONLY 2
• Reduce mortality by at least 20% and decrease sudden cardiac death 2
• Starting doses: Carvedilol 3.125 mg twice daily, Metoprolol succinate 12.5-25 mg once daily, Bisoprolol 1.25 mg once daily 2
• Target doses: Carvedilol 25-50 mg twice daily, Metoprolol succinate 200 mg once daily, Bisoprolol 10 mg once daily 2

4. ARNI (Preferred) or ACE Inhibitor/ARB

• Sacubitril/valsartan (ARNI) 49/51 mg twice daily is preferred over ACE inhibitors 2
• Provides at least 20% mortality reduction, superior to ACE inhibitors 2
• Target dose: 97/103 mg twice daily 2
• If ARNI not tolerated: ACE inhibitor (enalapril 10-20 mg twice daily, lisinopril 20-40 mg once daily) or ARB (valsartan 160 mg twice daily, losartan 150 mg once daily) 2
• CRITICAL: Never combine ACE inhibitor with ARNI due to angioedema risk 2

5. Loop Diuretics (For Volume Management)

• Essential for congestion control but do not reduce mortality 2
• Furosemide 20-40 mg once or twice daily, Torsemide 10-20 mg once daily, or Bumetanide 0.5-1.0 mg once or twice daily 2
• Titrate to achieve euvolemia (no edema, no orthopnea, no jugular venous distension), then use lowest dose that maintains this state 2

Titration Algorithm

Increase one drug at a time every 1-2 weeks using small increments until target or maximally tolerated dose is achieved, prioritizing SGLT2 inhibitor and MRA first (minimal BP effects), then beta-blocker, then ARNI. 2

• Monitor blood pressure, heart rate, renal function, and electrolytes at 1-2 weeks after each dose increment 2
• Modest increases in creatinine (up to 30% above baseline) are acceptable and should not prompt discontinuation 2
• Goal: Achieve optimal treatment within 2 months of diagnosis 2

Managing Low Blood Pressure During Optimization

Never discontinue or reduce GDMT for asymptomatic hypotension with adequate perfusion, as GDMT medications maintain efficacy and safety even in patients with baseline SBP <110 mmHg. 2

For Symptomatic Hypotension (SBP <80 mmHg or Major Symptoms):

1. Address reversible non-HF causes first:

   • Stop alpha-blockers (tamsulosin, doxazosin, terazosin, alfuzosin) 2
   • Discontinue other non-essential BP-lowering medications 2
   • Evaluate for dehydration, infection, or acute illness 2

2. Non-pharmacological interventions:

   • Compression leg stockings for orthostatic symptoms 2
   • Exercise and physical training programs 2
   • Adequate salt and fluid intake if not volume overloaded 2
   • Space out medication timing throughout the day 2

3. If symptoms persist, reduce GDMT in this specific order:

   • If heart rate >70 bpm: Reduce ACEi/ARB/ARNI dose first 2
   • If heart rate <60 bpm: Reduce beta-blocker dose first 2
   • Always maintain SGLT2 inhibitor and MRA (minimal BP effects) 2

Additional Therapies for Specific Subgroups

Ivabradine

• Indicated if heart rate ≥70 bpm in sinus rhythm despite maximally tolerated beta-blocker 2, 3
• NYHA class II-IV symptoms despite optimal medical therapy 3
• Starting dose: 2.5-5 mg twice daily 2
• Target: Maintain resting heart rate between 50-60 bpm 3
• Survival benefit is modest or negligible in the broad HFrEF population 2

Hydralazine/Isosorbide Dinitrate

• Indicated for self-identified Black patients with NYHA class III-IV symptoms despite optimal therapy 2
• Starting dose: Hydralazine 25 mg three times daily + Isosorbide dinitrate 20 mg three times daily 2
• Can prolong survival but may be inferior to ACE inhibitors for mortality 2

Device Therapy

Implantable Cardioverter-Defibrillator (ICD)

• Indicated for primary prevention in patients with symptomatic HF (NYHA Class II-III) and LVEF ≤35% despite ≥3 months of optimal medical therapy, who are expected to survive >1 year with good functional status 2
• Also indicated for secondary prevention in patients who have recovered from ventricular arrhythmia causing hemodynamic instability 2

Cardiac Resynchronization Therapy (CRT)

• Indicated for symptomatic HFrEF patients in sinus rhythm with QRS duration ≥150 msec and left bundle branch block (LBBB) morphology with LVEF ≤35% despite optimal medical therapy 2

---

Heart Failure with Preserved Ejection Fraction (HFpEF, EF >40%)

First-Line Therapy

SGLT2 inhibitors (dapagliflozin or empagliflozin) are the cornerstone of HFpEF treatment, reducing cardiovascular death and HF hospitalization. 1

SGLT2 Inhibitors

• Dapagliflozin 10 mg once daily or Empagliflozin 10 mg once daily 1
• Demonstrated benefit in DELIVER and EMPEROR-PRESERVED trials 1
• Effective regardless of diabetes status 1

Diuretics

• Use judiciously as needed to reduce congestion and improve symptoms 1
• Loop diuretics titrated to achieve euvolemia 1

Additional Therapies (Consider Based on Patient Characteristics)

• Mineralocorticoid Receptor Antagonists (Spironolactone): Demonstrated benefit in TOPCAT trial, particularly in Americas region 1
• ARNI (Sacubitril/Valsartan): Demonstrated benefit in PARAGON-HF trial, particularly in patients with EF closer to 40% and women 1
• ARBs (Candesartan): Demonstrated benefit in CHARM-PRESERVED trial 1

Beta-Blockers in HFpEF

• May be used in patients with specific indications: Prior myocardial infarction (for up to 3 years), angina, or atrial fibrillation 1
• Monitor exercise tolerance due to potential for chronotropic incompetence 1

Comorbidity Management in HFpEF

Management focuses on risk stratification and aggressive treatment of comorbidities, including hypertension, diabetes mellitus, obesity, atrial fibrillation, coronary artery disease, chronic kidney disease, and obstructive sleep apnea. 1

---

Management of Underlying Comorbidities

Hypertension in Heart Failure

Target systolic blood pressure of 130 mmHg, but not less than 120 mmHg, to avoid worsening cardiac output. 4

• GDMT medications (ARNI/ACE inhibitors, beta-blockers, MRAs) also treat hypertension 4
• Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they increase risk of worsening heart failure and hospitalization 2
• Avoid moxonidine, clonidine, and alpha-blockers as they can worsen heart failure 4

Diabetes Mellitus in Heart Failure

SGLT2 inhibitors are the preferred diabetes medication in patients with heart failure, providing cardiovascular benefit regardless of baseline diabetes status. 1, 2

• Metformin is relatively safe in stable heart failure 5
• Thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea 5
• Maintain glycemic control with HbA1c monitoring 4

Atrial Fibrillation in Heart Failure

• Long-term anticoagulants recommended according to CHA2DS2-VASc scores 5
• Beta-blockers indicated for rate control 1
• Consider rhythm control strategies in selected patients 5

Coronary Artery Disease in Heart Failure

• Coronary angiography remains the gold standard for diagnosis in patients with HF and angina refractory to antianginal medications 5
• Revascularization should be considered in eligible patients 1

Chronic Kidney Disease in Heart Failure

• Both volume status and cardiac performance are important for therapy guidance 5
• GDMT can be safely used with eGFR monitoring 2
• Modest increases in creatinine (up to 30% above baseline) are acceptable during GDMT optimization 2
• Worsening kidney function with successful decongestion is associated with lower mortality than failure to decongest with stable kidney function 2

Anemia and Iron Deficiency

• Iron supplementation can help improve symptoms in patients with HF and anemia 5
• Check ferritin and transferrin saturation 5

Obstructive Sleep Apnea

• Continuous positive airway pressure therapy helps avoid severe nocturnal hypoxia 5
• Screen patients with HF for sleep-disordered breathing 5

---

Critical Medications to AVOID in Heart Failure

Diltiazem or verapamil are absolutely contraindicated in HFrEF as they increase the risk of worsening heart failure and hospitalization. 2

• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) 2
• Thiazolidinediones (pioglitazone, rosiglitazone) 5
• Alpha-blockers (tamsulosin, doxazosin, terazosin, alfuzosin) 2, 4
• Moxonidine and clonidine 4
• Non-evidence-based beta-blockers (atenolol, propranolol) 2
• Triple combination of ACE inhibitor + ARB + MRA (due to hyperkalemia and renal dysfunction risk) 2
• ACE inhibitor combined with ARNI (due to angioedema risk) 2

---

Monitoring Requirements

Initial Diagnostic Workup

• Complete blood count, urinalysis, serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, fasting blood glucose (glycohemoglobin), lipid profile, liver function tests, and thyroid-stimulating hormone 1
• 12-lead electrocardiogram and chest radiograph (posterior-anterior and lateral) 1
• Two-dimensional echocardiography with Doppler to assess LVEF, left ventricular size, wall thickness, and valve function 1

Ongoing Monitoring During GDMT Optimization

• Blood pressure, heart rate, renal function, and electrolytes at 1-2 weeks after each dose increment 2
• More frequent monitoring in elderly patients and those with chronic kidney disease 2
• Daily weight monitoring to detect early decompensation 4

Monitoring for Hyperkalemia

• Potassium levels require close monitoring with MRAs 2
• If hyperkalemia develops, consider potassium binders (patiromer) rather than discontinuing life-saving medications 2
• Discontinuation of RAASi after hyperkalemia was associated with two to fourfold higher risk of subsequent adverse events 2

---

Common Pitfalls to Avoid

Target doses of all recommended drugs were simultaneously achieved in only 1% of eligible patients in real-world registries, with discontinuation rates as high as 55% for ACE inhibitors. 2

• Delaying initiation of all four medication classes simultaneously 2
• Accepting suboptimal doses without attempting titration 2
• Stopping medications for asymptomatic hypotension 2
• Using non-evidence-based beta-blockers 2
• Inadequate monitoring of renal function and electrolytes 2
• Down-titrating GDMT for asymptomatic low blood pressure before addressing reversible non-HF causes 2
• Discontinuing medications for modest increases in creatinine during decongestion 2

---

Referral Criteria for Advanced Heart Failure

Refer to a heart failure specialist when patients have persistent NYHA class III-IV symptoms despite optimal GDMT, recurrent hospitalizations, need for continuous or intermittent inotropic support, or consideration for advanced therapies (mechanical circulatory support, transplantation). 2, 4